Skip to main content
Figure 4 | Journal of Experimental & Clinical Cancer Research

Figure 4

From: A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma

Figure 4

JAK2/Stat3 is downstream target of SMC4. (A) Real-time quantitative PCR results on JAK2/Stat3 expression in HCC tissues and cell lines (T, HCC tissues; P, paracancerous tissues; N, non-tumor tissues). (B) Western blotting results showing that JAK2/Stat3 was upregulation in HCC cell lines (T, HCC tissues; P, paracancerous tissues; N, non-tumor tissues). (C) Western Blotting (left) and real-time quantitative PCR (right) results showing JAK2/Stat3 downregulation by SMC4-inhibit in 97-H and HepG2 cell lines (1–3, 97-H/HepG2; 4–6, 97-H/HepG2 -vector; 7–9, 97-H/HepG2-inhibit). (D) Co-immunoprecipitation assays showing that p-Stat3 (Tyr705) protein expression after silencing of SMC4 in 97-H and HepG2 cell lines (1–3, 97-H/HepG2; 4–6, 97-H/HepG2 -vector; 7–9, 97-H/HepG2-inhibit). (E) Western Blotting results showing JAK2/Stat3 changed by after miR-219 modulation with mimics and inhibitors in 97-H and HepG2 cell lines, and phosphorylation status (1, 97-H/ HepG2; 2, 97-H/HepG2 -vector; 3, 97-H/HepG2-minics; 4, 97-H/ HepG2-inhibitor ). GAPDH was used as a control. (*p < 0.05).

Back to article page